Helix BioPharma Corp. has announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations, reinforcing its executive leadership as the company prepares for a planned U.S. securities exchange listing and advances its clinical pipeline. The appointments are part of a strategic effort to strengthen legal, governance, and operational infrastructure to support the next phase of growth.
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma, emphasized the significance of these changes. “The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago,” he said. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix’s growth.”
Mehrling highlighted the company's progress on capital markets: “With the preparation of our base shelf prospectus underway and the auditor review of our second-quarter financials completed, we are executing on a clear capital markets roadmap as we prepare for our planned U.S. securities exchange listing. Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution. Together, they significantly strengthen our ability to deliver on our clinical, corporate and capital markets objectives.”
Helen Middleton brings over 30 years of experience in pharmacy, law, and the global life sciences industry, having worked with companies such as Sidley Austin LLP, Mundipharma International, Ipsen, and Abcam. As General Counsel, she will oversee legal affairs, governance, compliance, and strategic transactions. “The most exciting opportunities in biopharma are created when strong science is matched by strong execution,” Middleton said. “Helix has reached an important point in its evolution, and I look forward to helping build the legal and governance framework that supports the Company’s clinical and corporate ambitions.”
David Browning, with more than 30 years of experience in global clinical development and oversight of over 30 Phase I-III studies, will lead operational planning and execution for Helix’s programs, including LDOS007. “The opportunity ahead for Helix is compelling,” Browning said. “The Company has built an encouraging clinical foundation for L-DOS47, and I look forward to helping execute its next stage of development with the operational excellence required to bring this program forward, and, ultimately, to patients.”
These appointments mark a key milestone as Helix BioPharma advances its lead candidate L-DOS47, an antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company is also developing next-generation bi-specific antibody-drug conjugates and two pre-IND candidates: LEUMUNA and GEMCEDA. For more information, visit https://www.helixbiopharma.com/.
Helix BioPharma is listed on the TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). The company’s forward-looking statements are subject to risks and uncertainties, as detailed in its filings on SEDAR+ at www.sedarplus.ca.
